ENXTBR:ARGX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has argenx's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ARGX has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-7.8%

ARGX

-4.8%

BE Biotechs

-1.1%

BE Market


1 Year Return

99.1%

ARGX

19.5%

BE Biotechs

-19.7%

BE Market

Return vs Industry: ARGX exceeded the Belgian Biotechs industry which returned 22% over the past year.

Return vs Market: ARGX exceeded the Belgian Market which returned -19% over the past year.


Shareholder returns

ARGXIndustryMarket
7 Day-7.8%-4.8%-1.1%
30 Day0%-3.3%1.4%
90 Day-4.8%-4.4%-2.7%
1 Year99.1%99.1%20.4%19.5%-18.4%-19.7%
3 Year943.3%943.3%28.3%25.9%-27.1%-31.5%
5 Year2,268.4%2,268.4%48.9%45.1%-21.2%-29.3%

Price Volatility Vs. Market

How volatile is argenx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is argenx undervalued compared to its fair value and its price relative to the market?

46.3%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ARGX (€209.6) is trading below our estimate of fair value (€390.48)

Significantly Below Fair Value: ARGX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ARGX is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: ARGX is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ARGX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ARGX is overvalued based on its PB Ratio (6.1x) compared to the XE Biotechs industry average (4.5x).


Next Steps

Future Growth

How is argenx forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

54.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARGX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ARGX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ARGX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ARGX's revenue (66.4% per year) is forecast to grow faster than the Belgian market (6.8% per year).

High Growth Revenue: ARGX's revenue (66.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ARGX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has argenx performed over the past 5 years?

-67.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ARGX is currently unprofitable.

Growing Profit Margin: ARGX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ARGX is unprofitable, and losses have increased over the past 5 years at a rate of 67.1% per year.

Accelerating Growth: Unable to compare ARGX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).


Return on Equity

High ROE: ARGX has a negative Return on Equity (-28.22%), as it is currently unprofitable.


Next Steps

Financial Health

How is argenx's financial position?


Financial Position Analysis

Short Term Liabilities: ARGX's short term assets (€2.0B) exceed its short term liabilities (€197.8M).

Long Term Liabilities: ARGX's short term assets (€2.0B) exceed its long term liabilities (€208.2M).


Debt to Equity History and Analysis

Debt Level: ARGX is debt free.

Reducing Debt: ARGX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ARGX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ARGX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is argenx current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ARGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ARGX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARGX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ARGX's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Tim Van Hauwermeiren (48 yo)

12.25yrs

Tenure

€6,152,325

Compensation

Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, MBA, has been a Director at iTeos Therapeutics, Inc. since June 2018. Mr. Van Hauwermeiren is Member of Advisory Board of Forbion Growth Opportunities ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD7.27M) is above average for companies of similar size in the Belgian market ($USD2.31M).

Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Timothy Van Hauwermeiren
CEO & Executive Director12.25yrs€6.15m0.096%
€ 9.6m
Eric Castaldi
Chief Financial Officer6.5yrsno data0%
€ 0
R. Woods
Chief Operating Officer2.5yrsno data0%
€ 0
Hans de Haard
Chief Scientific Officer12.25yrsno data0.12%
€ 11.7m
Dirk Marcel Beeusaert
General Counsel3.5yrsno data0%
€ 0
Arjen Lemmen
Vice President of Corporate Development & Strategy1.33yrsno data0%
€ 0
Wim Parys
Chief Medical Officer1.25yrsno data0%
€ 0
Joke Comijn
Director Corporate Communications & Investor Relations (EU)no datano datano data
Marc Schorpion
Global Head of Human Resources1.83yrsno datano data
Andria Wilk
Global Head of Quality Assurance0.75yrno datano data
Beth DelGiacco
Vice President of Investor Relationsno datano datano data

2.5yrs

Average Tenure

56yo

Average Age

Experienced Management: ARGX's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Timothy Van Hauwermeiren
CEO & Executive Director12.25yrs€6.15m0.096%
€ 9.6m
J. deBethizy
Independent Non-Executive Director5.42yrs€709.67k0%
€ 0
Peter K. Verhaeghe
Independent Chairman of the Board6.25yrs€734.67k0%
€ 0
Werner Lanthaler
Independent Vice-Chairpersonno data€712.17k0.054%
€ 5.3m
Anthony Rosenberg
Independent Non-Executive Director3.5yrs€707.17k0%
€ 0
James Daly
Independent Non-Executive Director2.42yrs€707.17k0%
€ 0
Pamela M. Klein
Independent Non-Executive Director4.5yrs€699.67k0%
€ 0
David Lacey
Independent Non-Executive Director6.25yrs€707.17k0%
€ 0

5.4yrs

Average Tenure

60.5yo

Average Age

Experienced Board: ARGX's board of directors are considered experienced (5.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ARGX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.2%.


Top Shareholders

Company Information

argenx SE's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: argenx SE
  • Ticker: ARGX
  • Exchange: ENXTBR
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €9.923b
  • Shares outstanding: 47.34m
  • Website: https://www.argenx.com

Number of Employees


Location

  • argenx SE
  • Willemstraat 5
  • Breda
  • Noord-Brabant
  • 4811 AH
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARGXENXTBR (Euronext Brussels)YesOrdinary SharesBEEURJul 2014
0QW0LSE (London Stock Exchange)YesOrdinary SharesGBEURJul 2014
ARGN.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2014
ARGXBBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJul 2014
1AEDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2014
ARGXWBAG (Wiener Boerse AG)YesOrdinary SharesATEURJul 2014
ARGXNasdaqGS (Nasdaq Global Select)American Depository ReceiptsUSUSDMay 2017
A1RG34BOVESPA (Bolsa de Valores de Sao Paulo)BRDR - Depositary ReceiptBRBRLOct 2020

Biography

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candida ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 21:13
End of Day Share Price2020/10/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.